دورية أكاديمية
Capsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy
| العنوان: | Capsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy |
|---|---|
| المؤلفون: | Ann-Christin Franke, Romain Hardet, Lisa Prager, Martin Bentler, Mélanie Demeules, Philipp John-Neek, Nico Martin Jäschke, Teng Cheong Ha, Ulrich Thorsten Hacker, Sahil Adriouch, Hildegard Büning |
| المصدر: | Molecular Therapy: Methods & Clinical Development, Vol 29, Iss , Pp 238-253 (2023) |
| بيانات النشر: | Elsevier, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Genetics LCC:Cytology |
| مصطلحات موضوعية: | AAV capsid engineering, cancer immunotherapy, prime-boost, single administration, vaccine, Genetics, QH426-470, Cytology, QH573-671 |
| الوصف: | Immunotherapy has significantly improved treatment outcomes in various cancer entities. To enhance immunogenicity and efficacy, and to further broaden its applicability, co-administration of anti-tumor vaccines is considered as a promising strategy. Here, we introduce adeno-associated virus (AAV) vectors, widely used for in vivo gene therapy, as a potent cancer vaccine platform. Our AAV vector-based vaccine combines antigen display on the capsid surface with a vector-mediated antigen overexpression targeting different components of the immune system in a unique chronological order by a single intramuscular application. Thereby, both profound and long-lasting antigen-specific T and B cell immune responses were induced. Moreover, mice receiving the vaccine were protected against tumor growth, demonstrating its efficacy in two tumor models, including the low immunogenic and aggressive B16/F10-Ova melanoma model. Remarkably, this approach was even effective in conditions of a late tumor challenge, i.e., 80 days post-vaccination, between 88% (B16/F10-Ova melanoma) and 100% (EG7 thymoma) of mice remained tumor free. Thus, decorating AAV vector particles with antigens by capsid engineering represents a potent vaccine concept for applications in cancer immunotherapy. Its modular and versatile ''plug-and-play'' framework enables the use of tumor antigens of choice and the easy implementation of additional modifications to enhance immunogenicity further. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2329-0501 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S2329050123000463; https://doaj.org/toc/2329-0501 |
| DOI: | 10.1016/j.omtm.2023.03.010 |
| URL الوصول: | https://doaj.org/article/60289b2c07f7465484685690b5e11a75 |
| رقم الأكسشن: | edsdoj.60289b2c07f7465484685690b5e11a75 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 23290501 |
|---|---|
| DOI: | 10.1016/j.omtm.2023.03.010 |